X Li1, G Wang2, Z Lu1, M Chen1, J Tan1, X Fang3. 1. Department of Gerontology, Huai'an First People's Hospital, Nanjing Medical University, 6 Beijing Xi Road, Huai'an, 223300, Jiangsu, China. 2. Department of Urology, Huai'an First People's Hospital, Nanjing Medical University, 6 Beijing Road, Huai'an, 223300, Jiangsu, China. 3. Department of Gerontology, Huai'an First People's Hospital, Nanjing Medical University, 6 Beijing Xi Road, Huai'an, 223300, Jiangsu, China. drfangxiaozheng@163.com.
Abstract
PURPOSE: To investigate serum 25-hydroxyvitamin D 25(OH)D status and assess the predictability of outcome in patients with Graves' disease (GD) who received a patient-specific calculated dose of radioiodine therapy (RIT). METHODS: 128 patients with GD who received RIT from July 2010 to September 2010 were included. Pre-therapy serum levels of 25(OH)D, calcium, phosphorus, parathyroid hormone, free triiodothyronine, free thyroxine, thyroid stimulating hormone and creatinine were measured. 60 age- and BMI-matched healthy subjects were chosen as the normal control group. RESULTS: Post-therapy follow-up results revealed that therapy failed in 25.00 % of the patients. Serum 25(OH)D levels were found to be significantly lower in patients who failed in therapy. The prevalence of vitamin D deficiency in GD patients was significantly higher compared with control subjects (56.25 vs. 10.00 %, P < 0.001), and therapy failed in 27 (37.50 %) of these patients whose serum 25(OH)D levels < 20 ng/ml. Out of the 56 patients (43.75 %) in whom serum 25(OH)D levels ≥20 ng/ml, therapy was unsuccessful in only 5 (8.93 %). Cox regression analysis suggested that serum 25(OH)D levels <20 ng/ml might be an independent risk factor for predicting failure of RIT in GD patients (relative risk = 8.83, 95 % confidence interval = 3.34-23.38, P < 0.001). CONCLUSIONS: Serum 25(OH)D levels were lower in patients who failed than in those who succeeded in RIT of GD. Therefore, serum 25(OH)D < 20 ng/ml might be an independent risk factor for predicting failure of RIT in GD patients.
PURPOSE: To investigate serum 25-hydroxyvitamin D25(OH)D status and assess the predictability of outcome in patients with Graves' disease (GD) who received a patient-specific calculated dose of radioiodine therapy (RIT). METHODS: 128 patients with GD who received RIT from July 2010 to September 2010 were included. Pre-therapy serum levels of 25(OH)D, calcium, phosphorus, parathyroid hormone, free triiodothyronine, free thyroxine, thyroid stimulating hormone and creatinine were measured. 60 age- and BMI-matched healthy subjects were chosen as the normal control group. RESULTS: Post-therapy follow-up results revealed that therapy failed in 25.00 % of the patients. Serum 25(OH)D levels were found to be significantly lower in patients who failed in therapy. The prevalence of vitamin D deficiency in GDpatients was significantly higher compared with control subjects (56.25 vs. 10.00 %, P < 0.001), and therapy failed in 27 (37.50 %) of these patients whose serum 25(OH)D levels < 20 ng/ml. Out of the 56 patients (43.75 %) in whom serum 25(OH)D levels ≥20 ng/ml, therapy was unsuccessful in only 5 (8.93 %). Cox regression analysis suggested that serum 25(OH)D levels <20 ng/ml might be an independent risk factor for predicting failure of RIT in GDpatients (relative risk = 8.83, 95 % confidence interval = 3.34-23.38, P < 0.001). CONCLUSIONS: Serum 25(OH)D levels were lower in patients who failed than in those who succeeded in RIT of GD. Therefore, serum 25(OH)D < 20 ng/ml might be an independent risk factor for predicting failure of RIT in GDpatients.
Authors: M A Walter; M Christ-Crain; B Eckard; C Schindler; E U Nitzsche; J Müller-Brand; B Müller Journal: Eur J Clin Invest Date: 2004-05 Impact factor: 4.686
Authors: T Mete; Y Yalcin; D Berker; B Ciftci; S F Guven; O Topaloglu; H C Yavuz; S Guler Journal: J Endocrinol Invest Date: 2013-04-02 Impact factor: 4.256
Authors: Swayamsidha Mangaraj; Arun K Choudhury; Basanta M Swain; Pradosh K Sarangi; Binoy K Mohanty; Anoj K Baliarsinha Journal: Indian J Endocrinol Metab Date: 2019 Jan-Feb